NIH Funding Cut Left Less Money On R&D Table, Tariffs Would Add To Woes: Aragen’s CEO

IPR Challenges In India Being Addressed

 
• By Vibha Ravi
  
Aragen CEO Manni Kantipudi
Aragen CEO Manni Kantipudi Talks About US Tariffs, Manufacturing Shifts, Regulation And More (Aragen Life Sciences)

More from India

More from Interviews